


# NAVIGATION ÉLECTROMAGNÉTIQUE: POSSIBILITÉS ET LIMITES

*CC, DR. PAOLA GASCHE»*





# LUNG TERRITORY REACHABLE BY CONVENTIONAL BRONCHOSCOPY




# THE PROBLEM OF THE PERIPHERAL NODULE

Peripheral nodule less than 2cm of diameter can be reached by conventional bronchoscopy only in **30%** of cases (*14% if in the outer  $\frac{1}{3}$  portion of lung parenchyma*) *Chest 2003;123:115S-128S.*



# CONVENTIONAL APPROACH

Ultra thin bronchoscope (2mm) and fluoroscopic guidance; 64.7% of sensitivity (*Rooney CP, Respiration 2002;69:63-68*)







# BIOPSY & RADIOLOGICAL GUIDANCE

## **Guidance & fluoroscopy** (*Chest 2006;129:147-150*)

- Irradiation
- Visibility ? 40% (54/138) of < 2.2cm lesions are **not** visible


## **CT-scan trans-thoracic bx**

- From 65 to 90% of sensitivity depending on the type of lesion
- Requires immobility of the patient during procedure
- Risk of hemorrhage **(10-20%)**
- Risk of pneumothorax **(>30%)**



# PNEUMOTHORAX RISK OF TTNA

- **↑ with number of passes**  
37% one pass; 57% five passes
- **↑ with distance from pleura**  
15% 0 cm (pleura based); 50% 0-5 cm
- **↓ with lesion size**  
0-2 cm = 50%; 2-4 cm = 35%; >4 cm = 15%
- **↑ with presence of emphysema**  
With emphysema = 50% (chest tube 27%)  
Without emphysema = 35% (chest tube 9%)



Sources:

Cox et al. Radiology July 1999;212:165-168

# NODULE = REAL PROBLEM?



Procedure	Approx. #/year	Hospital Days	Reimbursement	Performed by
Diagnostic Bronchoscopy	3,500,000	1	\$1,700	Interventional Pulmonologist
Therapeutic Bronchoscopy	200,000	1-4	Up to \$5,000	Interventional Pulmonologist
CT-Guided Needle Biopsy	700,000	1	Up to \$4,500	Interventional Radiologist
Open Surgery	1,000,000	6	Up to \$70,000	Surgeon

Interventional Pulmonary procedures (Europe / N. America / Asia ~30% each)



# ELECTROMAGNETIC NAVIGATION SYSTEM


Based on regular GPS system






# COMPONENTS OF THE SYSTEM

## 1. Magnetic field; the board




# COMPONENTS OF THE SYSTEM

## 2. Magnetic field: electrodes



# COMPONENTS OF THE SYSTEM

## 3. Sensor



- Receptor of EM wave
- Position detected in 3 axes by software (X, Y, Z-axes, roll, pitch & yaw)
- Position shown on a monitor at a rate of 161 images/sec.



# COMPONENTS OF THE SYSTEM

## 3. The guide



- 4 wires
- Rotating handle
- 8 positions





# PROCEDURE

Pre-specified thoracic Ct-scan data (*Dicom CD*)  $\Rightarrow$  Upload of the images in the navigation system



Route planning

# PROCEDURE



3-D reconstruction &  
virtual bronchoscopy



Choice of the target  
(1 or more)



Choice of the  
pathway to the target




# PROCEDURE

Synchronisation of  
the virtual with the  
real bronchoscopy  
Images (FB 2.8mm)





Navigation toward  
target



# PROCEDURE





Navigation toward target(s) with steerable catheter inserted in a working channel





# PROCEDURE


Navigation toward target(s) with steerable catheter inserted in a working channel



# PROCEDURE: *TISSUE SAMPLING*

Once the target is reached:


- Lock working channel
- Remove steerable navigation catheter
- Use instruments to remove tissue samples





# ENB (ELECTROMAGNETIC NAVIGATION BRONCHOSCOPY)

## ROSE : Rapid On Site Evaluation



# MODIFICATION OF ENB PERFORMANCE

**Table 5.** Study-level characteristics associated with significant modification of ENB's performance.

		Nb of studies	Pooled outcome [95% CI]	p-values
Diagnostic yield				
General anesthesia	Yes	9	69.2% [60.6 – 76.7]	0.02
	No	7	57.5% [53.2 – 61.8]	
Sensitivity for malignancy				
ROSE	Yes	4	80.2% [72.1 – 86.4]	0.006
	No	10	66.3% [60.3 – 71.8]	
Diagnostic yield				
Fluoroscopy	Yes	6	56.3% [51.5 – 60.9]	0.006
	No	10	68.8% [61.3 – 75.4]	





# ENB(*inReach*<sup>TM</sup>): RESULTS

## Electromagnetic Navigation Bronchoscopy Performed by Thoracic Surgeons: One Center's Early Success

Daryl Phillip Pearlstein, MD, Curtis C. Quinn, MD, Charles C. Burtis, BS,  
Kwang Woo Ahn, PhD, and Aaron J. Katch, MS

Divisions of Cardiothoracic Surgery, and Biostatistics, Medical College of Wisconsin, Milwaukee; Division of Cardiothoracic Surgery, Waukesha Memorial Hospital, Waukesha; and Aurora Advanced Healthcare, Milwaukee, Wisconsin

*Table 1. Negative Predictive Value and Sensitivity Based on  
Lesion Size* **N=104**


Lesion Size (cm)	<1.5	1.5–2	>2	Overall
Negative predictive value	78%	20%	55%	56%
Sensitivity	78%	69%	85%	82%

Fisher exact test *p* value for negative predictive value: 0.141; Fisher exact test *p* value for sensitivity: 0.333.

(Ann Thorac Surg 2012;93:944–50)  
© 2012 by The Society of Thoracic Surgeons




# SENSITIVITY FOR MALIGNANCY




# Electromagnetic Navigation Bronchoscopy: Diagnostic Yield by Year

ENB diagnostic yield has increased significantly  
from 68.3% to 85%.



# ELECTROMAGNETIC NAVIGATION BRONCHOSCOPY (ENB) ALLOWS YOU TO:



## Navigate

Navigate to distal lesions for biopsy



## Stage

Stage lymph nodes



## Place

Place fiducial markers for radiation treatment



## Locate


Place markers to facilitate VATS



## Deliver

Guide high dose radiation catheters

# TRANSBRONCHIAL PLACEMENT OF FIDUCIAL MARKERS USING ENB






# TRANSBRONCHIAL PLACEMENT OF FIDUCIAL MARKERS USING ENB

superDimension® **superLock® Bands**  
(13-23mm: 3mm gold)




superDimension® **superLock® Coils**  
(5-10-20mm, 0.9, gold)



superDimension® **superLock Cobra®**  
Fiducial Marker  
(7mm : Nitinol & gold seed 3.5x0.8)


# Stereotactic Body Radiotherapy (SBRT/SRT)

- Uses a combination of precise patient positioning/immobilization to administer radiation with extreme accuracy
- Increasingly being used to treat patients with early-stage NSCLC who are not candidates for surgical resection or refuse surgery



# SBRT IN EARLY STAGE LUNG CANCER

- Studies show a **5-year survival** rate of 50% for early stage lung cancer patients that are inoperable or refuse surgery<sup>1-4</sup>
- Early data shows comparable results to surgery with **acceptable toxicity** and comparable local control and survival rates<sup>5-8</sup>




## SOURCES:

- 1) Sibley GS. (1998) Radiotherapy for patients with medically inoperable Stage I non-small cell lung carcinoma. Smaller volumes and higher doses: a review. *Cancer* 82:433-438.
- 2) Armstrong JG, et al. (1989) Radiation therapy for medically inoperable stage I and II non-small cell lung cancer. *Cancer Treat Rev.* 16(4):247-255.
- 3) Dosoretz DE, et al. (1996) Medically inoperable lung carcinoma: the role of radiation therapy. *Semin Radiat Oncol.* 6(2):98-104.
- 4) Kaskowitz L, et al. (1993) Radiation therapy alone for stage I nonsmall cell lung cancer. *Int J Radiat Oncol Biol Phys.* 27(3):517-523.
- 5) Timmerman R, et al. (2010) Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer *JAMA* 303(11):1070-1076.
- 6) Nagata Y, et al. (2005) Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. *Int J Radiat Oncol Biol Phys.* 63(5):1427-1431.
- 7) Timmerman R, et al. (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. *J Clin Oncol.* 24(30):4833-4839.
- 8) Lagerwaard FJ, et al. (2008) Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys.* 70(3): 685-692.


# COMMON SBRT/SRT SYSTEMS

- Novalis Tx<sup>®</sup>
- TomoTherapy HiArt<sup>®</sup>
- Varian Trilogy<sup>®</sup>
- Varian TrueBeam<sup>®</sup>
- Elekta Synergy<sup>®</sup>
- Elekta Axesse<sup>®</sup>
- Siemens Primatom<sup>®</sup>
- Accuray CyberKnife<sup>®</sup>



# SBRT/SRT USES


- Primary Treatment Modality – Curative
  - Inoperable patients (COPD, ILD)
  - Patients who refuse surgery
- (Neo) Adjuvant Treatment
  - Pre-operative treatment for subsequent surgical curative intent (Stage IIIA disease)
- Palliative Treatment





# Motion Management is Critical to SBRT


- Lung targets are dynamic
- Failure to manage motion may result in inaccurate dose delivery
- Preserves normal lung tissue



# Problems of Respiratory Motion


- Causes artifact during imaging acquisitions
- Target shape and volume uncertainty due to CT artifact
- Dose uncertainty if motion is not accounted for

Motion varies markedly between patients, indicating that an individual approach to respiratory management is required in SBRT



# RESPIRATORY GATING

Defined as a specific window in the breathing cycle, much like a baseball strike zone, when it is optimal to turn on the radiation beam. Ideally, this "**strike zone**" is a period of time in the breathing cycle when the tumor moves the least.




# RESPIRATORY TRACKING

Defined as delivering tightly contoured beams that move precisely with tumor motion throughout the respiratory cycle.



# ABDOMINAL COMPRESSION


Defined as using a compression board to help minimize tumor motion during breathing cycles.





# FIDUCIAL MARKERS FOR LUNG SBRT/SRT

Localization with fiducial markers directly into and/or around a lung tumor is considered an accurate way to aid respiratory motion management when delivering SBRT/SRT.



# IMPORTANCE OF FIDUCIAL MARKERS FOR AIDING MOTION MANAGEMENT

- Allows **synchronization** of patient's anatomy from imaging to radiation delivery, accounting for respiratory motion
- Allows **smaller/conformal radiation fields**; less radiation to adjacent critical structures, higher doses to primary tumors and potentially better control
- Internal fiducial markers are a **better surrogate of tumor motion** compared to an external marker

# FIDUCIAL PLACEMENT USING ENB

## Planning Phase



Target selected with planning software

## Navigation

Using navigation catheter under electromagnetic guidance

## Marker Placement – Several Methods

## Stereotactic Radiotherapy Procedure Proceeds



# THE ENB SOLUTION – CLINICAL DATA

## **Six (6) articles published on transbronchial placement of fiducial markers using ENB <sup>1-6</sup>**

- Fiducial markers successfully placed in over 80 patients
- 2-5 markers placed per tumor
- Lesion size varied from 0.8 cm to 6.5 cm in diameter
- Minimal migration and pneumothoracies reported

### *SOURCES:*

- 1) Harley, D, et al. Fiducial Marker Placement Using Endobronchial Ultrasound and Navigational Bronchoscopy for Stereotactic Radiosurgery: An Alternative Strategy. *Ann Thorac Surg* 2010; 89:368-374.
- 2) Schroeder, C, et al. Coil Spring Fiducial Markers Placed Safely Using Navigation Bronchoscopy in Inoperable Patients Allows Accurate Delivery of CyberKnife Stereotactic Radiosurgery *J Thorac Cardiovasc Surg*; 140:1137-1142.
- 3) Andrade, R. *Seminars in Thoracic and Cardiovascular Surgery* 2010; Vol 22, No 3.
- 4) Anatham, D, et al. Electromagnetic Navigation Bronchoscopy Guided Fiducial Placement for Robotic Stereotactic Radiosurgery of Lung Tumors – A Feasibility Study. *Chest* 2007; 132:930-935.
- 5) McGuire, F, et al. Radiotherapy Monitoring Device Implantation into Peripheral Lung Cancers: A Therapeutic Utility of Electromagnetic Navigational Bronchoscopy. *Jrl of Bronch* 2007; 14(3): 173-176.
- 6) Kupelian, P, et al. Implantation and Stability of Metallic Fiducials within Pulmonary Lesions. *J Radiation Oncology Biol Phys* 2007; 69(3): 777-785.

# CONCLUSIONS

## **1. Effective diagnostic technique**

- Successful diagnosis of peripheral lesions in 69-82% of cases
- No association with size of nodule
- Probable even higher success rates for lymph nodes

## **2. Safe diagnostic technique**

- Pneumothorax rate of 0-2.3%
- No need for irradiation
- Short learning curve

## **3. New option for SBRT/SBT**



